Uncovering the miRNA layer of genetic regulation will be part of the optimal approach to targeted therapy in breast cancer; this involves improving our understanding of molecular targets such as ER, PR and HER2/neu in addition to identifying novel molecular pathways and targets in order to predict response and to identify pathways of primary and acquired resistance to therapy. This evidence concerns the gene PGR and breast cancer.